Watchful Waiting for Adrenal Tumors | NYU Langone Health
NYU Langone experts may carefully monitor, rather than treat, small adrenal tumors that are not causing any symptoms.
Pulmonary Embolism | NYU Langone Health
NYU Langone doctors recognize the signs of pulmonary embolism, a dangerous blockage in the lungs, and move quickly to resolve the condition.
Support for Schizophrenia | NYU Langone Health
NYU Langone experts provide ongoing support to people with schizophrenia, a lifelong condition that is treatable with medication and therapy.
Staphylococcal Infections | NYU Langone Health
NYU Langone doctors diagnose and manage staphylococcus, or staph, infections and take steps to prevent a recurrence.
A Randomized Open-label Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-based Chemotherapy in Patients with EGFR-mutated Non-small Cell Lung Cancer and Disease Progression on EGFR Tyrosine Kinase Inhibitor Therapy
This is Phase 2/3 study testing a new medicine called iza-bren (also known as izalontamab brengitecan or BL-B01D1) for treating advanced lung cancer that has a specific mutation called EGFRmt. Iza-bren works in a special way: it targets two proteins, EGFR and HER3, which are often involved in cancer growth. It delivers a medicine that can kill cancer cells directly to the tumor. The goal of this study is to find the best dose of iza-bren and see how well it works compared to standard chemotherapy (a combination of platinum and pemetrexed). This study has two parts: phase 2 and phase 3. In Phase 2, the patients are randomly put into one of three groups. Once enough patients have been treated in Phase 2, the study will choose the best dose of iza-bren and move to Phase 3. In Phase 3, patients will randomly get either the chosen dose of iza-bren or standard chemotherapy. This phase will compare how well iza-bren works, how safe it is, and how well people can tolerate it, compared to the usual chemotherapy treatment (platinum-pemetrexed) for EGFRmt lung cancer. This part of the study is for patients whose cancer keeps growing even after using another medicine called EGFR-TKI. All patients will have frequent medical check ups and blood samples taken to see how their bodies are handling the study medicine. The study team will have special scans done for all patients to see how the cancer is responding to the study medicines. The study team will be monitoring the patients for potential side effects and safety concerns.
CBYL719F12201: EPIK-P2 Phase II double-blind study w/ upfront 16-week randomized placebo-controlled period to assess efficacy safety & pharmacokinetics of alpelisib (BYL719) in pediatric & adult patients w/ PIK3CA-related overgrowth spectrum (PROS)
This study will be the first prospective study of alpelisib in participants with PROS. Local overgrowth or hemihypertrophy, mostly progressive, is the most frequently observed manifestation of the disease, often causing functional and/or mobility impairment andreduction in health related quality of life. The first experience with alpelisib in overgrowth related to mutation in PIK3CA gene provides the direct evidence of clinical improvement in participants supporting PIK3CA inhibition as a promising therapeutic strategy in participants with PROS. PROS is a serious condition with no approved pharmacological treatment targeting the underlying cause of the disease. Current therapy includes debulking surgery, amputation, and/or endovascular occlusive procedures and mainly addresses symptoms and complications of the disease. There is a high unmet medical need for an effective systemic treatment.The purpose of this study is to assess the efficacy, safety/tolerability and evaluate pharmacokinetics (PK) of alpelisib in participants of different ages with confirmed diagnosis of PROS. As the disease continues throughout the participant life and may be diagnosed at different time points (Keppler-Noreuil et al 2014), the study will enroll adult participants (Group 1; treated with film-coated tablets (FCT)), 6-17 years old pediatric participants (Group 2; treated with FCT), and two exploratory sets of 2-5 years old pediatric participants (Group 3 treated with granules and Group 4 treated with FCT).Group 3 will be enrolled after the completion of the primary analysis when the efficacy, safety and PK data will be available from the participants in Groups 1 and 2 in addition to the data from Group 4 as available, in order to select the recommended dose forparticipants in Group 3. Recruitment of participants in Group 3 will start only after submission and approval of a Substantial Global Protocol Amendment specific to this group. Group 4 will be enrolled before Group 3 and immediately after implementation of this Global Protocol Amendment 01.
Adolescent Healthy Weight Program | NYU Langone Health
At the Adolescent Healthy Weight Program, part of Hassenfeld Children’s Hospital at NYU Langone, we offer medical and surgical weight loss.
Medication for Vasculitis | NYU Langone Health
For many people with vasculitis, NYU Langone doctors prescribe medications to reduce inflammation.
Bipolar Disorder | NYU Langone Health
NYU Langone mental health specialists offer expert treatment for bipolar disorder.
Recovery & Support for Dermatomyositis | NYU Langone Health
Doctors at NYU Langone provide follow-up care, annual screening tests, and mind-body wellness programs for people who have dermatomyositis.